Recent Finacing
Recent Raise
Galleon Pharmaceuticals develops medicines targeting disrupted breathing control—sleep apnea, COPD, ventilator weaning, drug‑induced respiratory depression, obesity hypoventilation—using licensed University of Louisville S‑nitrosothiol‑based drug combinations.
Focus Areas
Total Raised
Funding round